Investigating various parameters on the labeling efficiency of [67Ga]Ga-phytate and its absorbed dose estimation in humans based on mouse data

Abstract

One of the most significant and common methods for early detection of breast cancer in the world is lymphoscintigraphy. In clinical trials, [99mTc]Tc-phytate has shown remarkable results for the detection of metastatic axillary lymph nodes prior to surgery. It is expected that the introduction and development of an appropriate alternative radiopharmaceutical including 67Ga for lymphoscintigraphy will be an important deal in the clinic as the half-life of 67Ga is longer than that of 99mTc (78.25 hours versus 6 hours). Radiolabeling of phytic acid with 67Ga is conducted in this study. Based on radioactive thin layer chromatography (RTLC), the radiochemical purity (RCP) was estimated at >99%. The final product represented satisfactory stability under human serum conditions, which was calculated to be greater than 89% during 3 days of study. Pre-clinical studies confirmed the urinary system as the main excretion route for radiopharmaceuticals. A human estimation dosimetry study based on preclinical data was also presented.

Keywords

• lymphoscintigraphy
• radiopharmaceutical
• breast cancer
• lymph nodes